| Literature DB >> 25190505 |
Anne Vested1, Cecilia H Ramlau-Hansen2, Sjurdur F Olsen3, Jens Peter Bonde3, Henrik Støvring3, Susanne L Kristensen3, Thorhallur I Halldorsson2, Panu Rantakokko3, Hannu Kiviranta3, Emil H Ernst3, Gunnar Toft3.
Abstract
Persistent organochlorine pollutants (POPs) are ubiquitous, bioaccumulative compounds with potential endocrine-disrupting effects. They cross the placental barrier thereby resulting in in utero exposure of the developing fetus. The objective of this study was to investigate whether maternal serum concentrations of polychlorinated biphenyls (PCBs) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) during pregnancy are associated with son's semen quality and reproductive hormone levels. During 2008-2009, we recruited 176 male offspring from a Danish cohort of pregnant women who participated in a study in 1988-1989. Each provided semen and blood samples that were analyzed for sperm concentration, total sperm count, motility, and morphology, and reproductive hormone levels, respectively. The maternal blood samples were collected in pregnancy week 30 and were analyzed for the concentrations of six PCBs (PCB-118, -138, -153, -156, -170, and -180) and p,p'-DDE. The potential associations between in utero exposure to ΣPCBs (pmol/ml), Σdioxin like-(DL) PCBs (PCB-118 and -156) (pmol/ml), and p,p'-DDE and semen quality and reproductive hormone levels were investigated using multiple regression. Maternal median (range) exposure levels of ΣPCB, ΣDL-PCB, and p,p'-DDE were 10.0 (2.1-35.0) pmol/ml, 0.8 (0.2-2.7) pmol/ml, and 8.0 (0.7-55.3) pmol/ml, respectively, reflecting typical background exposure levels in the late 1980s in Denmark. Results suggested that in utero exposure to ΣPCB, ΣDL-PCB, and p,p'-DDE was not statistically significantly associated with semen quality measures or reproductive hormone levels. Thus, results based on maternal PCB and p,p'-DDE concentrations alone are not indicative of long-term consequences for male reproductive health; however, we cannot exclude that these POPs in concert with other endocrine-modulating compounds may have adverse effects.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25190505 PMCID: PMC4241711 DOI: 10.1530/REP-13-0488
Source DB: PubMed Journal: Reproduction ISSN: 1470-1626 Impact factor: 3.906
Figure 1Flow chart for recruitment of participants.
Maternal serum levels of six PCB congeners and p,p′-DDE.
|
| |
|---|---|
| Wet weight serum concentrations (ng/ml) | |
| PCB-118 | 0.17 (0.05–0.59) |
| PCB-138 | 0.75 (0.14–2.58) |
| PCB-153 | 1.46 (0.27–5.81) |
| PCB-156 | 0.10 (0.02–0.34) |
| PCB-170 | 0.38 (0.08–1.14) |
| PCB-180 | 0.71 (0.15–2.44) |
| | 2.55 (0.23–17.59) |
| Lipid-adjusted serum concentrations (ng/g lipid) | |
| PCB-118 | 20 (6–60) |
| PCB-138 | 88 (16–263) |
| PCB-153 | 165 (31–591) |
| PCB-156 | 12 (2–37) |
| PCB-179 | 43 (9–148) |
| PCB-180 | 81 (18–277) |
| | 288 (31–2208) |
Characteristics of 166 young men by tertiles of maternal pregnancy week 30 serum ΣPCB and p,p′-DDE concentrations.
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
| Low (2.14–8.02pmol/ml), | Medium (>8.02–11.47pmol/ml), | High (>11.47–34.99pmol/ml), |
| Low (0.73–6.30pmol/ml), | Medium (>6.30–10.63pmol/ml), | High (>10.63–55.32pmol/ml), |
| |
| Characteristics of sons | ||||||||
| BMI (kg/m2), median (p25–p75) | 22.7 (20.9–24.4) | 22.6 (20.5–24.5) | 23.0 (20.6–24.1) | 0.77 | 22.3 (20.3–24.0) | 22.8 (20.8–24.4) | 22.8 (20.9–24.2) | 0.64 |
| History of reproductive tract disease | 7 (13.7) | 8 (16.0) | 7 (13.2) | 0.91 | 9 (17.7) | 7 (13.7) | 6 (11.5) | 0.67 |
| Current/ occasional smoker | 26 (49.1) | 25 (49.0) | 29 (54.7) | 0.80 | 27 (51.9) | 29 (54.7) | 24 (46.2) | 0.67 |
| Characteristics of mothers | ||||||||
| Mother smoking during pregnancy | 18 (33.3) | 15 (27.3) | 18 (35.3) | 0.65 | 16 (30.2) | 18 (33.3) | 17 (32.1) | 0.94 |
| Socioeconomic status (Total annual household income 1987) | ||||||||
| <200 000 DKK | 23 (46.9) | 21 (39.6) | 15 (30.0) | 0.22 | 21 (43.8) | 21 (38.9) | 17 (34.0) | 0.61 |
| >200 000 DKK | 26 (53.1) | 32 (60.4) | 35 (70.0) | 0.22 | 27 (56.3) | 33 (61.1) | 33 (66.0) | 0.61 |
| Serum total lipid level (g/l), median p25–p75) | 8.2 (7.5–9.0) | 8.6 (7.6–9.3) | 9.0 (7.8–10.3) | 0.01 | 8.3 (7.5–9.3) | 8.6 (7.6–9.6) | 8.5 (7.7–10.1) | 0.43 |
| Characteristics of sons' semen and serum | ||||||||
| Duration of abstinence (h) | ||||||||
| ≤48 | 23 (41.8) | 33 (58.9) | 35 (64.8) | 0.04 | 23 (41.8) | 35 (62.5) | 33 (61.1) | 0.05 |
| ≥49 | 32 (58.2) | 23 (41.1) | 19 (35.2) | 0.04 | 32 (58.2) | 21 (37.5) | 21 (38.9) | 0.05 |
| Min. from ejaculation to semen analysis, median (p25–p75) | 43.5 (30.0–55.0) | 40.0 (27.5–55.0) | 50.0 (35.0–60.0) | 0.25 | 37.5 (25.0–50.0) | 45.0 (30.0–57.5) | 50.0 (35.0–55.0) | 0.11 |
| Spillage at semen sampling | 14 (27.5) | 14 (26.4) | 16 (30.8) | 0.88 | 10 (19.6) | 15 (28.3) | 19 (36.5) | 0.16 |
| Time for blood sampling | ||||||||
| 0730–0929 | 19 (35.2) | 15 (27.3) | 19 (35.2) | 0.60 | 18 (32.7) | 16 (29.1) | 19 (35.9) | 0.79 |
| 0930–1129 | 29 (53.7) | 29 (52.7) | 24 (44.4) | 0.60 | 31 (56.4) | 28 (50.9) | 23 (43.4) | 0.79 |
| 1130– | 6 (11.1) | 11 (20.0) | 11 (20.4) | 0.60 | 6 (10.9) | 11 (20.0) | 11 (20.8) | 0.79 |
Numbers are based on complete case data and indicate number (percentage) unless otherwise stated.
Differences across tertiles of ΣPCB and p,p′-DDE exposure where tested by Kruskal–Wallis test.
History of reproductive tract disease include: inguinal hernia, varicocele, testicular hydrocele, incarcerated hernia, phimosis, torsio testis, clamydia, gonorrhea, and epididymitis combined into one variable (yes/no).
Differences across tertiles of ΣPCB and p,p′-DDE exposure where tested by χ 2-test.
Characteristics of semen, testicular size, and reproductive hormone for 173 young Danish men stratified by tertiles of maternal pregnancy week 30 serum ΣPCB concentrations (pmol/ml).
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| Low ΣPCB ( | Medium ΣPCB ( | High ΣPCB ( | β-coeff (95% CI) | Trend | Medium ΣPCB | High ΣPCB | Adjusted ln β-coeff (95% CI) | Adjusted trend |
| Sperm concentration (106/ml) | 173 | 37 (13–64) | 37 (15–60) | 42 (23–91) | 0.22 (−1.50; 1.95) | 0.80 | −8 (−52; 36) | 22 (−24; 68) | 0.03 (−0.02; 0.07) | 0.25 |
| Total sperm count (106) | 129 | 123 (53–223) | 130 (42–215) | 92 (55–221) | −0.52 (−5.75; 4.70) | 0.84 | −12 (−65; 41) | 18 (−38; 73) | 0.02 (−0.03; 0.08) | 0.44 |
| Semen volume (ml) | 129 | 3.0 (2.2–4.2) | 3.1 (2.2–3.9) | 2.8 (1.8–4.0) | −0.02 (−0.08; 0.05) | 0.57 | 5 (−15; 26) | 0 (−22; 21) | −0.002 (−0.02; 0.02) | 0.86 |
| Percentage progressive spermatozoa | 173 | 66 (52–74) | 64 (52–73) | 65 (52–69) | −0.28 (−0.69; 0.12) | 0.16 | −1 (−10; 9) | −1 (−11; 9) | −0.003 (−0.01; 0.006) | 0.49 |
| Percentage motile spermatozoa | 173 | 74 (66–80) | 72 (66–76) | 73 (66–76) | −0.21 (−0.51; 0.09) | 0.17 | −2 (−8; 5) | −2 (−8; 4) | −0.002 (−0.008; 0.004) | 0.52 |
| Percentage morphologically normal spermatozoa | 161 | 8 (4–12) | 9 (4–14) | 9 (4–12) | 0.05 (−0.13; 0.23) | 0.58 | 4 (−43; 51) | −15 (−64; 34) | −0.01 (−0.06; 0.03) | 0.59 |
| Mean testicular volume (ml) | 173 | 15 (11–20) | 15 (13–20) | 15 (11–20) | 0.05 (−0.12; 0.22) | 0.57 | 2 (−11; 16) | −2 (−16; 12) | 0.003 (−0.01; 0.02) | 0.71 |
| Testosterone (nmol/l) | 173 | 23 (19–26) | 20 (17–23) | 21 (18–27) | 0.01 (−0.15; 0.18) | 0.88 | −11 (−21; −1) | −1 (−11; 10) | 0.0004 (−0.01; 0.01) | 0.94 |
| Free testosterone (nmol/l) | 173 | 0.55 (0.45–0.62) | 0.47 (0.41–0.57) | 0.53 (0.45–0.62) | −0.001 (−0.005; 0.002) | 0.41 | −11 (−22; −1) | −1 (−13; 10) | −0.0009 (−0.01; 0.01) | 0.86 |
| Estradiol (nmol/l) | 173 | 0.10 (0.09–0.13) | 0.09 (0.08–0.11) | 0.10 (0.08–0.11) | −0.0006 (−0.002; 0.0003) | 0.18 | −16 (−28; −5) | −4 (−16; 8) | −0.003 (−0.01; 0.009) | 0.64 |
| LH (IU/l) | 173 | 4.5 (3.3–6.0) | 4.1 (3.1–4.9) | 4.4 (3.6–5.7) | 0.01 (−0.04, 0.07) | 0.70 | −13 (−28, 1) | −2 (−17; 13) | −0.0009 (−0.02; 0.01) | 0.90 |
| FSH (IU/l) | 173 | 2.9 (2.0–4.1) | 3.1 (2.3–4.6) | 3.0 (2.4–4.3) | 0.01 (−0.05; 0.08) | 0.73 | 7 (−13; 27) | −1 (−20; 21) | 0.001 (−0.02; 0.02) | 0.90 |
| Inhibin B (pg/ml) | 173 | 219 (158–259) | 225 (172–283) | 221 (176–278) | 0.95 (−1.65; 3.56) | 0.47 | 5 (−11; 21) | 8 (−8; 24) | 0.008 (−0.007; 0.02) | 0.28 |
| SHBG (nmol/l) | 173 | 26 (21–33) | 27 (22–32) | 27 (21–34) | 0.19 (−0.12;0.49) | 0.23 | −4 (−17; 9) | −1 (−14; 13) | 0.001 (−0.01; 0.01) | 0.88 |
Note: p, percentile.
Adjustment: all multiple regression results were adjusted for the history of reproductive tract disease, the son's BMI; son's smoking status, maternal smoking during pregnancy, socioeconomic status, and total blood lipid concentration. Sperm concentration, total sperm count, progressive spermatozoa, motile spermatozoa, semen volume, and testicular volume were adjusted for abstinence time, sperm concentration was adjusted for spillage during semen sample collection, progressive spermatozoa and motile spermatozoa were adjusted for time from ejaculation to semen analysis, and the reproductive hormones were adjusted for time of day of blood sampling.
Trends on ΣPCB concentrations (continuous data) were tested by robust linear regression analysis (untransformed crude data) and multiple regression analysis (adjusted data).
Characteristics of semen, testicular size, and reproductive hormone for 173 young Danish men stratified by tertiles of maternal pregnancy week 30 serum ΣDL-PCB concentrations.
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| Low ΣDL-PCB ( | Medium ΣDL-PCB ( | High ΣDL-PCB ( | β-coeff (95% CI) | Trend | Medium ΣDL-PCB | High ΣDL-PCB | Adjusted β-coeff (95% CI) | Adjusted trend |
| Sperm concentration (106/ml) | 173 | 37 (13–62) | 36 (16–61) | 42 (22–94) | 4.03 (−15.23; 23.28) | 0.68 | −2 (−46; 43) | 22 (−25; 70) | 0.25 (−0.24; 0.73) | 0.32 |
| Total sperm count (106) | 129 | 123 (27–215) | 93 (45–198) | 128 (54–265) | 11.91 (−41.37; 65.18) | 0.66 | 2 (−52; 56) | 33 (−23; 90) | 0.26 (−0.36; 0.87) | 0.41 |
| Semen volume (ml) | 129 | 3.0 (2.2–4.2) | 3.1 (2.1–3.9) | 3.0 (2.0–4.1) | −0.004 (−0.68; 0.67) | 0.99 | 7 (−14; 28) | 9 (−13; 31) | 0.07 (−0.17; 0.30) | 0.57 |
| Percentage progressive spermatozoa | 173 | 66 (52–74) | 65 (52–74) | 65 (52–69) | −2.25 (−6.80; 2.29) | 0.33 | 2 (−8; 12) | −1 (−11; 9) | −0.02 (−0.13; 0.09) | 0.71 |
| Percentage motile spermatozoa | 173 | 74 (63–79) | 74 (69–80) | 72 (64–76) | −1.99 (−5.58; 1.60) | 0.28 | 3 (−3; 9) | −2 (−9; 4) | −0.02 (−0.09; 0.05) | 0.56 |
| Percentage morphologically normal spermatozoa | 161 | 9 (5–13) | 7 (3–12) | 9 (6–13) | 0.24 (−1.88; 2.36) | 0.82 | −21 (−68; 25) | −15 (−65; 35) | −0.16 (−0.70; 0.39) | 0.56 |
| Mean testicular volume (ml) | 173 | 15 (11–20) | 18 (13–20) | 15 (12–20) | 0.75 (−1.07; 2.57) | 0.42 | 9 (−4; 23) | 4 (−10; 18) | 0.05 (−0.09; 0.20) | 0.49 |
| Testosterone (nmol/l) | 173 | 22 (18–25) | 21 (17–23) | 21 (19–27) | −0.01 (−1.94; 1.92) | 0.99 | −7 (−18; 3) | −2 (−13; 9) | −0.003 (−0.12; 0.11) | 0.95 |
| Free testosterone | 173 | 0.53 (0.43–0.61) | 0.51 (0.43–0.60) | 0.54 (0.43–0.61) | −0.01 (−0.06; 0.03) | 0.60 | −4 (−16; 7) | −2 (−13; 10) | −0.01 (−0.13; 0.11) | 0.85 |
| Estradiol (nmol/l) | 173 | 0.10 (0.08–0.12) | 0.09 (0.08–0.11) | 0.10 (0.08–0.11) | −0.006 (−0.02; 0.004) | 0.25 | −6 (−18; 6) | −4 (−17; 8) | −0.04 (−0.17; 0.09) | 0.50 |
| LH (IU/l) | 173 | 4.5 (3.6–5.8) | 4.1 (3.1–5.1) | 4.4 (3.6–5.6) | 0.09 (−0.57; 0.76) | 0.78 | −11 (−26; 4) | −2 (−18; 13) | −0.005 (−0.17; 0.16 | 0.95 |
| FSH (IU/l) | 173 | 2.9 (2.0–4.3) | 3.1 (2.3–4.5) | 3-0 (2.4–4.3) | 0.001 (−0.73; 0.73) | 1.00 | 8 (−12; 29) | 1 (−20; 22) | −0.006 (−0.23; 0.21) | 0.95 |
| Inhibin B (pg/ml) | 173 | 219 (158–261) | 225 (181–281) | 224 (159–277) | 13.74 (−16.97; 44.45) | 0.38 | 4 (−12; 20) | 7 (−10; 23) | 0.11 (−0.06; 0.29) | 0.20 |
| SHBG (nmol/l) | 173 | 26 (22–34) | 26 (21–31) | 28 (22–35) | 1.47 (−2.20; 5.15) | 0.43 | −9 (−23; 4) | −3 (−17; 10) | −0.01 (−0.15; 0.13) | 0.89 |
Note: p, percentile.
Adjustment: all multivariable regression results were adjusted for the history of reproductive tract disease, the son's BMI; son's smoking status, maternal smoking during pregnancy, socioeconomic status, and total lipid. Sperm concentration, total sperm count, progressive spermatozoa, motile spermatozoa, semen volume, and testicular volume were adjusted for abstinence time; sperm concentration was also adjusted for spillage during semen sample collection; progressive spermatozoa and motile spermatozoa were also adjusted for time from ejaculation to semen analysis; reproductive hormones were also adjusted for time of day of blood sampling.
Trends on Σdioxin-like PCB concentrations (continuous data) were tested by robust linear regression analysis (untransformed crude data) and multiple regression analysis (adjusted data).
Characteristics of semen-, testicular size-, and reproductive hormone for 173 young Danish men stratified by tertiles of maternal pregnancy week 30 serum p,p′-DDE concentrations.
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| Low | Medium | High | β-coeff (95% CI) | Trend | Medium | High | Adjusted β-coeff (95% CI) | Adjusted trend |
| Sperm concentration (106/ml) | 173 | 40 (16–62) | 33 (18–63) | 40 (16–93) | 0.83 (−0.17; 1.83) | 0.10 | −5 (−51; 40) | 14 (−32; 61) | 0.01 (−0.006; 0.03) | 0.15 |
| Total sperm count (106) | 129 | 122 (60–222) | 113 (43–199) | 117 (49–267) | 0.80 (−1.73; 3.34) | 0.53 | −14 (−68; 40) | 9 (−48; 66) | 0.01 (−0.01; 0.03) | 0.38 |
| Semen volume (ml) | 129 | 3.2 (2.4–4.3) | 2.7 (1.9–3.5) | 3.0 (2.0–4.1) | −0.01 (−0.03; 0.01) | 0.41 | −13 (−33; 8) | −8 (−30; 14) | −0.002 (−0.01; 0.007) | 0.71 |
| Percentage progressive spermatozoa | 173 | 70 (59–74) | 63 (49–70) | 65 (53–70) | −0.04 (−0.24; 0.15) | 0.66 | −7 (−17; 3) | −5 (−15; 5) | 0.0005 (−0.004; 0.005) | 0.81 |
| Percentage motile spermatozoa | 173 | 76 (71–81) | 72 (66–77) | 72 (63–76) | −0.13 (−0.29; 0.03) | 0.11 | −5 (−11; 1) | −7 (−13; −1) | −0.001 (−0.004; 0.001) | 0.34 |
| Percentage morphologically normal spermatozoa | 173 | 8 (4–14) | 7 (4–13) | 10 (6–12) | 0.02 (−0.09; 0.12) | 0.74 | −6 (−59; 46) | 11 (−45; 68) | −0.002 (−0.03; 0.03) | 0.90 |
| Mean testicular volume (ml) | 173 | 15 (11–20) | 15 (12–20) | 15 (13–20) | 0.03 (−0.04; 0.11) | 0.41 | 5 (−9; 19) | 8 (−6; 22) | 0.002 (−0.004; 0.008) | 0.50 |
| Testosterone (nmol/l) | 173 | 21 (18–24) | 21 (17–24) | 21 (19–27) | 0.07 (−0.02; 0.16) | 0.13 | −2 (−12; 9) | 7 (−3; 18) | 0.003 (−0.001; 0.008) | 0.13 |
| Free testosterone | 173 | 0.51 (0.44–0.60) | 0.54 (0.42–0.61) | 0.52 (0.44–0.61) | 0.001 (−0.0007; 0.003) | 0.24 | 2 (−9; 13) | 3 (−8; 14) | 0.003 (−0.002; 0.007) | 0.29 |
| Estradiol (nmol/l) | 173 | 0.10 (0.08–0.11) | 0.09 (0.08–0.12) | 0.10 (0.08–0.12) | 0.00009 (−0.0003; 0.0005) | 0.67 | −4 (−16; 8) | −1 (−14; 11) | 0.0009 (−0.004; 0.006) | 0.73 |
| LH (IU/l) | 173 | 4.3 (3.5–5.4) | 4.4 (3.7–5.5) | 4.4 (3.1–5.8) | 0.02 (−0.008; 0.05) | 0.17 | −5 (−20; 11) | −5 (−20; 11) | 0.002 (−0.005; 0.009) | 0.57 |
| FSH (IU/l) | 173 | 2.9 (2.2–4.1) | 3.0 (2.1–4.4) | 3.1 (2.1–4.5) | 0.0001 (−0.03; 0.03) | 1.00 | −1 (−21; 19) | −3 (−24; 17) | −0.0002 (−0.009; 0.009) | 0.97 |
| Inhibin B (pg/ml) | 173 | 226 (158–271) | 209 (168–255) | 231 (180–288) | −0.07 (1.26; 1.12) | 0.91 | −5 (−20; 11) | 8 (−8; 24) | 0.001 (−0.006; 0.008) | 0.75 |
| SHBG (nmol/l) | 173 | 25 (20–34) | 24 (20–30) | 30 (24–37) | 0.09 (−0.09; 0.26) | 0.33 | −8 (−21; 5) | 12 (−2; 25) | 0.003 (−0.003; 0.009) | 0.37 |
Note: p, percentile.
Adjustment: all multivariable regression results were adjusted for the history of reproductive tract disease, the son's BMI; son's smoking status, maternal smoking during pregnancy, and socioeconomic status. Sperm concentration, total sperm count, progressive spermatozoa, motile spermatozoa, semen volume, and testicular volume were adjusted for abstinence time; sperm concentration was also adjusted for spillage during semen sample collection; progressive spermatozoa and motile spermatazoa were also adjusted for time from ejaculation to semen analysis; reproductive hormones were also adjusted for time of day of blood sampling.
Trends p,p′-DDE concentrations (continuous data) were tested by robust linear regression analysis (untransformed crude data) and multiple regression analysis (adjusted data).
Characteristics of mothers and sons at baseline (pregnancy week 30) and follow-up according to the level of participation.
|
|
|
|
|
|
|---|---|---|---|---|
| Maternal | ||||
| ΣPCBs (pmol/ml), median (p25–p75) | 10.1 (7.3–12.9) | 10.4 (7.6–13.0) | 9.0 (6.6–12.2) | 0.12 |
| ΣDioxin-like-PCBs (pmol/ml), median (p25–p75) | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) | 0.8 (0.6–1.0) | 0.11 |
| | 8.2 (5.2–12.4) | 7.3 (4.9–11.2) | 8.0 (5.1–11.9) | 0.48 |
| Maternal age (years), mean ( | 29.6 (4.4) | 29.0 (4.2) | 28.3 (4.5) | 0.03 |
| Prepregnancy BMI (kg/m2), median (p25–p75) | 21.0 (19.8–22.3) | 20.7 (19.5–22.7) | 21.2 (19.1–23.1) | 0.77 |
| Nulliparous, | 112 (64) | 96 (61) | 83 (58) | 0.60 |
| Smoking during pregnancy, | 55 (33) | 53 (37) | 63 (47) | 0.03 |
| High social class, | 96 (60) | 87 (64) | 77 (61) | 0.78 |
| Blood total lipid level (g/l), median (p25–p75) | 8.6 (7.7–9.6) | 8.8 (7.9–10.0) | 8.7 (7.9–9.6) | 0.33 |
| Alcohol during pregnancy (g/day), median (p25–p75) | 2.0 (0.4–4.6) | 1.5 (0–4.4) | 1.5 (0–3.5) | 0.53 |
| Male offspring follow-up | ||||
| BMI (kg/m2), median (p25–p75) | 22.2 (20.5–24.1) | 22.4 (20.7–24.4) | – | 0.50 |
| Current/occasional smoker, | 83 (50) | 66 (43) | – | 0.24 |
| History of reproductive tract disease, | 23 (14) | 11 (7) | – | 0.06 |
Kruskal–Wallis test.
One-way ANOVA test.
χ 2-test.
BMI is calculated from anthropometric measures based on self-reported values.
Wilcoxon rank-sum test.